Abstract
Extranodal nasal type NK/T cell lymphoma (ENKTL) is a highly aggressive non-Hodgkin lymphoma. Due to its low occurrence even in prevalent areas, there has been no large sample randomized controlled clinical trials. Therefore, no standard therapeutic strategy is currently identified in this disease. Tumor cells are insensitive to conventional anthracyclines-containing chemotherapy because of high expression of multi-drug resistant gene 1. Regimens that incorporate the use of L-asparaginase or gemcitabine result in substantial improvements in overall response rate and are promising treatment for ENKTL. Targeted therapy, immunomodulatory therapy and hematopoietic stem cell transplantation are still under research. Key words: Lymphoma, extranodal NK-T-cell; Drug therapy; Hematopoietic stem cell transplantation
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
